Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Bristol Myers BMY

Verkoop
 Koop

BristolMyers live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

A graph showing us stock futures mildly decline after S&P 500 record close.
Vanessa L 2025 Jan 24, 06:30

US Stock Futures Decline After S&P 500 Record Close

Shares Stocks US500
Frances Wang 2025 Jan 23, 16:00

Tesla stock prediction 2025: forecast for the tesla share price

TSLA Stocks Shares
Frances Wang 2025 Jan 23, 16:00

Zuckerberg sold stock: He Sells $2 Billion in Meta Stock Amid AI Push

Stocks
Frances Wang 2025 Jan 23, 16:00

Financial compensation news: Car compensation may affect working people

CFD Trading
Hand holding mobile with Tesla logo and upward stock arrow, reflecting Tesla Model Y price increase.
Vanessa L 2025 Jan 23, 11:00

Tesla Model Y Price Hike Sparks Debate Across Canada

TSLA Stocks Shares
Gold bullion and U.S. dollar bills, reflecting trends in gold coin prices.
Vanessa L 2025 Jan 23, 10:20

Gold Coin Prices Steady Amid Dollar Weakness

Gold USD Commodities Fed
Apple stock news with Chinese flag on smartphone, highlighting market challenges.
Vanessa L 2025 Jan 23, 08:30

Apple Stock News Amid Revenue Diversification

Stocks Shares AAPL China
BOJ rate hike
Tommy Yap 2025 Jan 22, 17:00

Morning Note: BOJ’s Rate Hike: How Will It Shape Markets?

BoJ Forex

Info

Spread

0.37

Spread (%)

0.6275 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

115788791808

Uitstaande aandelen

2028179968

Datum winstcijfer (volgende)

2001-08-07

Div. rend.

2025-02-03

Ex-dividenddatum

2025-01-03

Jaarlijks verwachte dividendpercentage

2.48

Jaarlijks verwachte dividendrendement

0.0435

Winst per aandeel

-3.58

Meer informatie over dit instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot
Live Chat